Form 4: SAB Biotherapeutics Director Eddie Joe Sullivan Reports Stock Option Grants
SEC Form 4 Filing
Eddie Joe Sullivan, a director and President of SAB Biotherapeutics, reported the acquisition of stock options on July 15, 2024.
Summary
- On July 15, 2024, Eddie Joe Sullivan, a director and President of SAB Biotherapeutics, Inc., reported the acquisition of stock options.
- Sullivan received a one-time grant of options for 46,528 shares at an exercise price of $5.40, which are fully vested.
- He also received a one-time grant of options for 4,447 shares at an exercise price of $2.90, vesting over a period from July 15, 2025, to July 15, 2028.
- These awards were made under the company's 2021 Omnibus Equity Incentive Plan, as amended.
- Following the transaction, Sullivan directly owns 46,528 stock options at $5.40 and 4,447 stock options at $2.90.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock option grants, which is neutral in sentiment. It reflects standard executive compensation practices.
Positives
- The grant of stock options to a director and officer aligns their interests with those of the shareholders.
- The vesting schedule for a portion of the options encourages long-term commitment from the executive.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Regeneron, and Gilead Sciences also utilize stock options to incentivize their executives.
- The vesting schedules and exercise prices are generally aligned with industry norms to retain talent and drive performance.
Stakeholder Impact
- The stock option grants could incentivize management to improve company performance, benefiting shareholders.
- Employees may view the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 07/15/2024 | Date of the stock option grants. |
| 07/15/2025 | First vesting date for the 4,447 stock options. |
| 07/15/2028 | Final vesting date for the 4,447 stock options. |
| 07/17/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.